© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Prulifloxacin didn’t just appear out of thin air. It arrives from a long line of research in the fluoroquinolone field. Scientists in the 1980s kept a close eye on increasing bacterial resistance, looking for drugs that could take on the most persistent infections. Morphing earlier quinolones into more advanced fluoroquinolones delivered antibiotics that packed a stronger punch, covered a wider bacterial range, and worked for trickier infections. Prulifloxacin landed in Italy during the 1990s, after careful work to boost absorption and power. Researchers managed to give doctors a new tool for urinary and respiratory infections, filling a need created by growing resistance to older drugs. The launch of Prulifloxacin taught the pharmaceutical world something about evolution: you solve a problem, new problems show up, and only creative thinking moves medicine forward.
Anyone reading the label sees Prulifloxacin listed as an oral fluoroquinolone prodrug, meaning it converts to its active form—ulifloxacin—once inside the human body. Drug-makers often pursue prodrugs because they handle tough stability challenges and improve how the body takes up medicine. Prulifloxacin typically comes in tablet form for adult prescription use. It tackles routine and complex infections, and is best known in hospitals and clinics where doctors suspect multi-drug-resistant bacteria. Healthcare providers depend on it most for urinary tract infections, bronchitis, and sometimes for traveler’s diarrhea or complicated abdominal infections.
You won’t pick out Prulifloxacin by smell or taste, but scientists see it as a white-to-light yellow crystalline powder that barely dissolves in water. Its chemical formula—C18H19F2N3O6S—packs two fluorine atoms, a sulfonyl group, and a piperazine ring. This structure makes it stubbornly stable under normal storage and gives it the edge to survive the digestive journey. The melting point crosses 120°C, which supports its long-lasting stability at room temperatures. Prulifloxacin’s low water solubility triggers some challenges during oral formulation, but the prodrug nature overcomes most hurdles, keeping doses predictable and dosing schedules simple for patients.
Each manufacturer must follow clear quality markers: content uniformity, purity (usually above 98%), and strict control of degradation products. Labels report the salt form, dose (typically 600 mg per tablet), directions for use, plus clear warnings about use in children, pregnant women, and people with certain health issues. Pharmacopoeias track critical specifications like particle size, microbial load, and moisture content to maintain consistent performance. Prulifloxacin labeling often includes guidance to avoid antacids or iron supplements within two hours of a dose, due to the risk of reduced drug uptake.
Drug makers stick with careful organic syntheses. Prulifloxacin comes together through a multi-step reaction sequence: core quinolone synthesis, strategic fluorination, cyclization to introduce rings, and sulfonylation to add the signature group. Protecting groups shield delicate sites along the way, and the final deprotection steps yield the pure active ingredient. Purification demands repeated crystallization and tight controls on residual solvents, usually monitored through robust analytical chemistry. These process details don’t only create a pure drug; they also decide the price and the environmental impact linked to its production. Waste management, efficiency improvements, and solvent recovery all factor in, reflecting a broader move in pharma to tighten up sustainability.
The backbone of Prulifloxacin offers avenues for tweaking: fluorine substitutions change bacterial spectrum, N-alkylation modifies how long the drug stays active, and side-chain shifts tune up absorption. Researchers occasionally test ester modification to create new prodrugs designed for better bioavailability or to escape some drug-resistance mechanisms. Prulifloxacin uniquely features a proline ester at one end—an innovation that lets the drug slip through the gut more efficiently, only converting to ulifloxacin with the help of body enzymes. Many in the field still search for ways to skirt around growing bacterial resistance through chemistry, but few changes beat the original proline ester design for practical oral dosing.
Pharmacies and chemical suppliers use a handful of names—Prulifloxacin, CAS 123447-62-1, and sometimes “prulifloxacino” or “UL-CEF.” Branded names shift from region to region, with “Unidrox” gaining traction in southern Europe and some Asian markets. While chemical catalogs and research papers list its structure and salts in various languages, the parent molecule rarely changes, keeping international research transparent.
Strict safety measures surround Prulifloxacin from manufacturing through handling and dispensing. Production facilities enforce ventilation and PPE use since airborne particles can aggravate skin and mucous membranes. Pharmacists, too, train staff on correct storage: keep away from heat, moisture, and incompatible chemicals. On the clinical side, monitoring for tendon rupture, neuropathy, and QT prolongation remains crucial. Doctors must report every suspected adverse event to track real-world safety. Though Prulifloxacin often helps people with tough infections, clinicians weigh every risk and avoid it in patients with known quinolone allergies. Regulatory guidelines like Good Manufacturing Practice (GMP) help each batch reach the market with tight consistency and minimal impurities.
Urinary tract infections stay right at the top of Prulifloxacin’s uses, especially in adults facing multi-drug resistant E. coli strains. Acute bronchitis, chronic obstructive pulmonary flare-ups, and complicated intra-abdominal infections form the next most common group. Hospitals use it with caution for conditions like typhoid fever or traveler’s diarrhea when other choices fail or local resistance makes alternatives risky. Some veterinarians consider it for tough cases in companion animals under specialist guidance, though human medicine remains its main field. Doctors always base use on careful bacterial identification and sensitivity tests to stretch the life of this antibiotic class as much as possible.
Medical journals show a steady flow of studies on Prulifloxacin over the past decade, ranging from resistance patterns to combination therapy. Some labs fashion new analogs designed to outmaneuver beta-lactamase-producing bacteria. Others test strategic pairing with older beta-lactams or macrolides to delay resistance. Researchers also focus on new delivery forms—nanoparticles, extended-release tablets, or fixed-dose combos—to improve patient outcomes and adherence. In silico (computer-based) studies drive leads for building the next generation of fluoroquinolones, spotlighting Prulifloxacin as a reliable chemical platform to learn from both its strengths and weaknesses.
Careful toxicology runs through every phase of Prulifloxacin’s journey from lab to clinic. Early studies found it mostly safe, but flagged skeletal toxicity for growing children and cartilage damage in young animals—a class problem for quinolones. Adult studies exposed rare but serious events like tendon rupture, nerve pain, and some heart rhythm changes. Post-marketing surveillance continues to update risk profiles, since the human body doesn’t always play by textbook rules. Kidney impairment, liver changes, and unpredictable allergies mean doctors must review patient history before starting anyone on this drug. Modern trials balance antimicrobial benefit with the need to protect patient safety, using hard data over anecdote at every step.
The story of Prulifloxacin is not yet finished. With bacterial resistance outpacing new drugs, pharmaceutical innovation faces a squeeze. Manufacturers, researchers, and prescribers look for smarter stewardship, reducing unnecessary antibiotic prescribing and pushing for faster, more accurate infection diagnostics. Scientists hope to engineer smarter prodrug and delivery systems to keep molecules effective and safer. Some researchers explore local-delivery patches or inhaled forms to target infections without raising systemic risks. Looking ahead, collaboration across countries, hospitals, and labs will likely shape how drugs like Prulifloxacin keep their value. As new resistance genes appear and spread, chemistry, clinical vigilance, and global policy all play a hand in deciding Prulifloxacin’s role for future generations.
Ask anyone who’s had a stubborn urinary tract or respiratory infection, and they’ll say the path to relief can feel endless. Prulifloxacin enters the story as an antibiotic shaped for these exact battles. Unlike penicillin or older options, it belongs to the fluoroquinolone group. These are known for stopping bacterial DNA from replicating, which shuts down the infection right at the source.
Doctors reach for Prulifloxacin mostly to treat urinary tract infections (UTIs), including complicated cases that don’t budge easily. I’ve seen this drug offered for respiratory issues like bronchitis and sinus infections, particularly in adults who might not find relief from common antibiotics. My pharmacist friends mention it’s mostly found in tablet form, which brings a sense of comfort for patients who dislike injections.
Friends and family often ask if it’s just another pill in the endless lineup. Not quite. Resistant bacteria have become a big public health challenge, making the effectiveness of today’s antibiotics matter much more. Prulifloxacin remains valuable because it hits targets that older drugs sometimes miss, especially against Gram-negative bacteria—these are the tough types causing high fevers and lingering infections.
Looking at published medical research, studies highlight Prulifloxacin’s steady performance against tough cases of pyelonephritis (a kidney infection I once saw nearby relatives struggle with) and complicated lower urinary tract infections. Reports from the International Journal of Antimicrobial Agents note how its once-daily dose helps patients stick to the course, heightening the chances for full recovery. Adherence means fewer relapses and resistance problems down the road.
Fluoroquinolones like Prulifloxacin bring benefits but aren’t free from concerns. I remember a patient feeling relieved after a UTI, only to later learn about rare risks of tendon rupture and nerve problems. The U.S. Food and Drug Administration and European Medicines Agency highlight these rare but serious side effects. Doctors weigh these risks against the infection’s severity and often save Prulifloxacin for tough cases.
On another note, elderly patients and those with kidney issues need special consideration. It’s not for children. Some people have a hard time processing the medication fully, leading to an increased risk of side effects. I always advise friends to speak up about any symptoms that feel off while using any antibiotic, not just this one.
Patients and healthcare professionals can support smarter antibiotic use. I find that clear communication plays a huge part. Patients should finish the entire treatment unless a doctor says otherwise and report any new or unexpected symptoms. Reducing misuse means more tools remain effective for the next person—and for those future days when nothing else seems to work.
Bacteria keep evolving, which pushes researchers and drugmakers to develop newer or reimagined antibiotics. Prulifloxacin shows how blending precision targeting with straightforward dosing can make a real difference in tackling persistent infections. For people battling repeat or resistant infections, having a reliable option counts for a lot.
Prulifloxacin turns up in clinics for folks battling bacterial infections. It steps in where common antibiotics fail or for harder-to-solve cases like urinary tract infections. Being a fluoroquinolone, it does a solid job against stubborn bacteria, but the body doesn't always welcome it with open arms. As someone who's asked doctors tough questions about side effects and watched family members deal with antibiotics, I’ve seen how important it is to have the facts before popping any pill.
Upset stomach lands on the top of the list. Nausea, loose stools, or tummy cramps appear shortly after starting. I've watched relatives swap cheerful conversation for quiet groans, hoping the medicine wouldn't hit too hard. In many cases, eating a small meal helps, but not always. Most see these problems fade as the body gets used to the medication, though some need to call the doctor and try something else. National drug safety agencies point out these gut-related symptoms in up to fifteen percent of cases.
A restless mind can't be ignored. People on prulifloxacin sometimes walk around plagued by headaches or dizziness. For a handful, sleeping gets tough. Anxiety, feeling jittery, or even confusion rarely develop. After talking to a pharmacist, I learned that older adults need to pay special attention, as these symptoms crank up risk for falls or further confusion. The U.S. Food and Drug Administration cautions about these reactions—especially in folks with a history of seizures.
Pain in the muscles or tendons sneaks up on some patients. Teenagers, athletes, or folks over sixty face more risk. The Achilles tendon takes the brunt. The pain may start as mild soreness and ramp up to full-on swelling or even a snap. The warning label screams about stopping right away if tendon problems show up. Watching a neighbor limp around for weeks drove home how real this risk is. Most recover, but the scare lingers.
Rashes, itching, or hives pop up every so often. Rarely, more serious reactions like swelling of the face or trouble breathing show up. I worked at a clinic where an allergic reaction sent a patient rushing to the emergency room. Patients with a record of drug allergies need to tread carefully. Healthcare providers need to check the file with each prescription.
Prulifloxacin doesn’t play nicely with sunlight. Even cloudy days can turn a light walk into a recipe for sunburn. Redness, rash, or peeling show up faster. The advice to slap on sunscreen, wear a hat, and skip long sun exposure comes from actual patient stories—not just the fine print.
People with diabetes, especially those using insulin or pills, notice highs and lows more often. Watching blood sugar closely and ringing the doctor for wild swings helps prevent headaches or worse. Researchers documented unpredictable effects on sugar control, pushing doctors to double-check before handing out this prescription to diabetics.
Knowing the risks ahead of time stops delays in getting help if something goes wrong. Doctors need a full history—other medicines, allergies, age, and daily habits—before choosing prulifloxacin. Patients asking questions at the pharmacy window skip plenty of trouble. No single medicine fits all, and it pays to weigh the side effects against the infection being treated. Open talk and careful monitoring open the door to safer choices—and gentler recoveries.
Prulifloxacin turns up in clinics and pharmacies as one of those antibiotics nobody learns about unless they pick up a prescription. It handles common bacterial infections – the ones that sideline people from work or, for kids, from school: respiratory tract issues, urinary tract problems, and even some types of gastroenteritis. The way to take Prulifloxacin often becomes a hot topic not only among patients but also among pharmacists who want to make sure everyone understands how to get better without setbacks.
Doctors usually recommend Prulifloxacin as an oral tablet. Unlike medications taken many times a day, this one often enters a routine just once every 24 hours. Swallowing the tablet whole with water works best, ideally after eating, since this tends to cut down on stomach upset. Forgetting this advice leads to a bitter taste and nausea—a reality anyone who’s made that mistake remembers well.
Missed doses happen, and that's normal life. The best thing is to take a missed dose as soon as possible. Two tablets at the same time bring on much more trouble than they're worth, so doubling up isn't the answer. Spacing each dose about the same time each day helps the body keep a steady fight against infection, and regular reminders set in a mobile phone take some of the stress off.
A pharmacist once told me that antibiotics collect trouble when people improvise. Skipping doses, splitting pills, or stopping once symptoms fade only helps bacteria regroup. That’s not just advice; studies in global public health show that bacteria grow stronger in places where people misuse antibiotics. Folks build up resistant bugs not just in themselves, but spread them around the whole community.
The length of Prulifloxacin treatment depends on the problem being fixed. For a run-of-the-mill urinary tract infection, three to seven days tend to work for most adults. Serious infections—especially in lungs or more complicated organs—might need a stretch closer to two weeks. Doctors figure out the timeline based on body size, severity, and how the first few days go. Children and older adults may need adjustments to avoid side effects or to match how their kidneys process the medication, so nobody should ever borrow pills from a friend, no matter how much both folks might want a shortcut to relief.
Early warning signs sometimes get ignored. Prulifloxacin can clash with antacids, iron supplements, or dairy products. These block the medicine and stop it from doing its job. Anyone picking up a new medication during treatment—whether a supplement, a prescription from another doctor, or even an over-the-counter pain reliever—should let their pharmacist know. They’ve seen every combination and can spot problems quickly.
Some people develop tendon pain or swelling, and that's a reason to get help. The class of antibiotics Prulifloxacin belongs to—fluoroquinolones—sometimes causes these side effects, especially in athletes, older adults, or those taking steroids.
Clear instructions from doctors and pharmacists always trump whatever search results show up online. Bringing questions to medical visits and double-checking drug labels keeps everything straight. Ticking doses off on a calendar, drinking extra water, and feeding the body well all help the healing process. Sharing pills never solves the problem. Finishing the prescribed course, even after symptoms vanish, guards against recurring and harder-to-treat infections.
Tackling infections isn’t just about prescriptions or lab tests—it’s about teamwork between patient knowledge, clear communication, and professional support. That’s how Prulifloxacin delivers real results.
Looking at any antibiotic, it’s tempting to focus only on how quickly it knocks out an infection. Prulifloxacin, part of the fluoroquinolone family, usually steps in for urinary tract infections and sometimes for respiratory issues. Some will feel better in just a day or two. But ignoring the safety side can bring real trouble, and it’s easy for those risks to slip past people just wanting relief.
The World Health Organization flags that inappropriate use of antibiotics helps drive resistance, making drugs less helpful over time. With prulifloxacin, doctors keep an even closer eye because adverse reactions can run serious. Before swallowing that first dose, folks ought to talk through some basics with their doctor.
If kidneys don’t run at full strength, it spells trouble for prulifloxacin. The body clears this drug through the kidneys. Damage can set in quickly if someone has chronic kidney conditions or reduced kidney function. A simple blood test, like eGFR or creatinine, will pinpoint this. If function is down, a different medication or adjusted dosage would suit better.
Elderly people often feel the effects more strongly. Weakness, confusion, and tendon injuries appear more in older patients, even when doses seem normal. Add additional medicines (like steroids), and the risk for tendon rupture—especially the Achilles—rises. Doctors have seen this in their own clinics and flagged it for years.
Children and teenagers usually get steered away from prulifloxacin altogether. Their growing cartilage stands vulnerable, and compared to other antibiotics, there’s little upside versus the bone and tendon risk. Specialists recommend safer options, saving prulifloxacin for when nothing else works.
People allergic to other fluoroquinolone antibiotics could set off a life-threatening response by taking prulifloxacin. Doctors will ask about past medications and reactions to confirm it’s safe to prescribe.
It’s not just about upset stomach or dizziness. Prulifloxacin can spark serious side effects. Some people develop nerve pain—numbness, burning, tingling—that may linger long after stopping the medicine. Reports in The Lancet described cases where these symptoms lasted months or, in rare cases, never fully resolved.
Mental health changes can happen, too. Agitation, confusion, even hallucinations have shown up, often startling those who expected nothing more than a quick fix. For folks with a history of seizures or mental illness, this risk demands honest conversation.
Mixing prulifloxacin with certain drugs amps up trouble. Quinidine, sotalol and other medicines that extend the heart’s QT interval interact dangerously, and this isn’t just a drugstore trivia question. I once watched a patient taking both suffer a heart rhythm problem that sent them to the ER. Prescribers need the full medication list, not just the current bottle.
Supplements and antacids matter, too. Calcium, magnesium, aluminium and iron can all block prulifloxacin from fully entering the body. A few hours’ difference between taking these and the antibiotic usually keeps things safe.
Taking prulifloxacin makes sense only if the likely benefits outweigh the dangers. No one should start it without a real conversation about past health, medications and allergies. Antibiotic resistance depends not just on drug companies but also on individual decisions—by both doctors and patients—to use these medicines wisely.
Standing in a doctor’s office with a prescription in hand, especially during pregnancy or breastfeeding, feels weighty. There’s more at play than knocking out an infection. Prulifloxacin, a fluoroquinolone antibiotic, pops up on prescription slips now and then, often for urinary or respiratory tract infections. People often turn to the internet or healthcare providers asking, “Can I take this safely while pregnant or nursing?”
Real-world evidence on prulifloxacin during pregnancy remains scarce. Drug safety often comes down to animal studies or data from similar medicines. With fluoroquinolones as a group, medical literature reports a link between these drugs and cartilage problems in animal fetuses. Human data stays limited for prulifloxacin in particular. For most doctors, this uncertainty flashes a big yellow warning light.
The U.S. Food and Drug Administration classifies most fluoroquinolones as not recommended for use in pregnancy, unless benefits clearly outweigh the risks. No large group studies exist monitoring children born to mothers who took prulifloxacin during pregnancy. Without that sort of follow-up, the jury stays out. Professional guidelines from sources like the American College of Obstetricians and Gynecologists leave prulifloxacin off the safe medication list for expectant mothers.
Times get tougher for new parents hoping to nurse safely after infection hits. Prulifloxacin passes into breast milk, as do most drugs in its family. Researchers have limited data on its effects in breastfeeding infants. Reports on similar antibiotics turned up possible changes to gut bacteria in babies and a low risk of joint effects. Pediatricians tend to err on the side of caution, steering mothers toward older antibiotics with more safety data. Choices like penicillins or certain cephalosporins make a difference here. If those can’t tackle the infection, a doctor might reconsider, explaining potential side effects and helping parents weigh them against untreated illness.
I’ve watched parents sift through medical jargon online, feeling overwhelmed by lists of risks and warnings. The decision hardly ever feels simple. Doctors balancing the urgency of a mother’s infection against the unknowns of drug safety rarely take decisions lightly. In my experience, communication makes the difference. Providing clear, specific advice—naming which drugs have time-tested safety records during pregnancy or lactation—cuts through confusion. Better yet, involving a pharmacist can help address practical questions about medication timing and alternatives.
If all options appear risky, healthcare teams sometimes ask about “pumping and dumping” breast milk, pausing breastfeeding through the course of treatment and using formula for a stretch. This approach’s success relies on the specific drug and how fast it leaves the mother’s system. Even then, evidence to support these choices is thin.
A gap exists in how much we know about newer drugs like prulifloxacin in vulnerable groups. Drug companies and researchers face pressure to design better pregnancy and lactation safety studies. Public drug registries and large international studies would go a long way here. Meanwhile, regular communication between patients and their care teams matters more than ever. No one-size-fits-all answer exists for every scenario, but sticking to medications with proven records during pregnancy and breastfeeding often reduces risk for families.
| Names | |
| Preferred IUPAC name | 1-(cyclopropyl)-6-fluoro-7-[(2-oxo-1,3-dioxolan-4-yl)methyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| Other names |
Afloxa Megrax Pruquin Unidrox |
| Pronunciation | /ˌpruːlɪˈflɒksəsɒn/ |
| Identifiers | |
| CAS Number | 123447-62-1 |
| Beilstein Reference | 3925881 |
| ChEBI | CHEBI:145610 |
| ChEMBL | CHEMBL1229675 |
| ChemSpider | 61953 |
| DrugBank | DB01123 |
| ECHA InfoCard | 03cf7fbd-ae38-47d2-a775-b0d6adfc9f40 |
| EC Number | EC 3.5.2.6 |
| Gmelin Reference | 952572 |
| KEGG | D05575 |
| MeSH | D000077245 |
| PubChem CID | 71361 |
| RTECS number | UF7G9P5578 |
| UNII | BN5PQ644B8 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C18H19F2N3O4 |
| Molar mass | 395.402 g/mol |
| Appearance | White or pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.12 |
| Vapor pressure | 2.97E-17 mmHg |
| Acidity (pKa) | 6.3 |
| Basicity (pKb) | 8.45 |
| Magnetic susceptibility (χ) | -73.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.653 |
| Dipole moment | 2.13 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 373.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | The standard enthalpy of formation (ΔfH⦵298) of Prulifloxacin is **-117.6 kJ/mol**. |
| Std enthalpy of combustion (ΔcH⦵298) | -5832 kJ/mol |
| Pharmacology | |
| ATC code | J01MA17 |
| Hazards | |
| Main hazards | May cause gastrointestinal disturbances, hypersensitivity reactions, tendon rupture, and central nervous system effects. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | ADR, RX, INJ, TAB, RXM |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. Read label before use. If medical advice is needed, have product container or label at hand. Wash hands thoroughly after handling. Avoid contact during pregnancy/while nursing. |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Lethal dose or concentration | LD50 (oral, rat): >5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 = 3080 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 600 mg once daily |
| IDLH (Immediate danger) | Not Listed |
| Related compounds | |
| Related compounds |
Ulifloxacin Afloxacin Balofloxacin Finafloxacin Besifloxacin |
